- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Osteoporosis Giant cell tumour of bone Bone metastases
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 452KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 83KB)
Denosumab – November 2024
Denosumab; Injection 60 mg in 1 mL pre-filled syringe; Jubbonti®; Injection 120 mg in 1.7 mL; Wyost®
Last updated
30 May 2025